{"generic":"Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir","drugs":["Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir","Stribild"],"mono":[{"id":"930276-s-0","title":"Generic Names","mono":"Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir"},{"id":"930276-s-1","title":"Dosing and Indications","sub":[{"id":"930276-s-1-4","title":"Adult Dosing","mono":"<b>HIV infection:<\/b> 1 tablet (elvitegravir 150 mg\/cobicistat 150 mg\/emtricitabine 200 mg\/tenofovir disoproxil fumarate 300 mg) ORALLY once a day with food "},{"id":"930276-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy have not been established in pediatric patients "},{"id":"930276-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>hepatic impairment, mild or moderate:<\/b> no dosage adjustment necessary<\/li><li><b>hepatic impairment, severe:<\/b> use not recommended<\/li><li><b>renal impairment (CrCl 70 mL\/min or less):<\/b> do not initiate therapy<\/li><li><b>renal impairment (CrCl drops below 50 mL\/min during treatment):<\/b> discontinue therapy<\/li><\/ul>"},{"id":"930276-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>HIV infection<br\/>"}]},{"id":"930276-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues in combination with other antiretrovirals. The elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate combination is not approved for the treatment of chronic hepatitis B virus (HBV) infection and the safety and efficacy have not been established in patients coinfected with HBV and HIV-1. Severe acute exacerbations of hepatitis B have been reported in patients coinfected with HBV and HIV-1 who have discontinued emtricitabine or tenofovir disoproxil fumarate. Monitor hepatic function upon discontinuation of therapy in patients coinfected with HIV-1 and HBV and follow-up for at least several months thereafter.<br\/>"},{"id":"930276-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930276-s-3-9","title":"Contraindications","mono":"Concomitant use with alfuzosin, rifampin, ergot derivatives (dihydroergotamine, ergotamine, methylergonovine), cisapride, St John's wort, lovastatin, simvastatin, pimozide, triazolam, oral midazolam, or sildenafil when dosed for the treatment of pulmonary arterial hypertension (greater than 25 mg in 48 hours) <br\/>"},{"id":"930276-s-3-10","title":"Precautions","mono":"<ul><li>Black Box Warnings:<\/li><li>-- Lactic acidosis and severe hepatomegaly with steatosis, including fatalities, have been reported with tenofovir disoproxil fumarate in combination with other antiretrovirals; risk is increased in women, obese patients, prolonged nucleoside exposure, or patients with known risk factors for liver disease; interrupt use if suspected<\/li><li>-- Hepatitis B virus (HBV) and HIV-1 coinfection; severe acute HBV exacerbations, including liver decompensation and liver failure, may occur upon discontinuation of therapy; monitoring recommended<\/li><li>-- Hepatotoxicity may occur; even in patients with no risk factors; interrupt therapy if suspected<\/li><li>Endocrine and Metabolic:<\/li><li>-- Body fat redistribution or accumulation, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and cushingoid appearance, have been reported<\/li><li>Musculoskeletal<\/li><li>-- Bone mineral density (BMD) decreases, bone fractures, and osteomalacia (associated with proximal renal tubulopathy) have been reported with tenofovir; monitoring recommended for patients at risk; consider proximal renal tubulopathy in patients presenting with persistent or worsening bone or muscle symptoms<\/li><li>Hepatic:<\/li><li>-- Severe hepatic impairment (Child-Pugh Class C); use not recommended<\/li><li>Immunologic:<\/li><li>-- Immune reconstitution syndrome has been reported; further evaluation and treatment may be necessary<\/li><li>-- Autoimmune disorders, including Graves disease, polymyositis, and Guillain-Barr  syndrome, have been reported in the setting of immune reconstitution; may occur many months after initiation of therapy<\/li><li>Renal:<\/li><li>-- Osteomalacia associated with proximal renal tubulopathy has been reported; condition may manifest as bone pain or pain in extremities<\/li><li>-- Renal impairment; discontinue if CrCl declines to less than 50 mL\/min during treatment and do not initiate if CrCl less than 70 mL\/min; additional monitoring recommended in patients at risk of renal impairment<\/li><li>-- Renal adverse events (eg, acute renal failure, Fanconi syndrome) have been reported; risk may be increased with concomitant use of drugs that reduce renal function or compete for active tubular secretion; monitoring recommended, especially in patients at risk of renal dysfunction or with prior renal events; consider alternative to NSAIDs in at-risk patients<\/li><li>Concomitant Use:<\/li><li>-- Concomitant or recent use of nephrotoxic agents (including acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides), or use of multiple or high-dose NSAIDs should be avoided<\/li><li>-- Use with other agents containing cobicistat, elvitegravir, emtricitabine, tenofovir, or lamivudine is not recommended<\/li><li>-- Avoid use with adefovir dipivoxil<\/li><li>-- Use with other antiretroviral products containing ritonavir is not recommended<\/li><li>-- Use with colchicine in patients with renal or hepatic impairment is not recommended<\/li><li>-- Use with rifabutin or rifapentine is not recommended<\/li><li>-- Use with salmeterol is not recommended<\/li><li>-- Use with avanafil, boceprevir, or telaprevir is not recommended<\/li><\/ul>"},{"id":"930276-s-3-11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"930276-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"930276-s-4","title":"Drug Interactions","sub":[{"id":"930276-s-4-13","title":"Contraindicated","mono":"<ul><li>Alfuzosin (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Colchicine (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dihydroergotamine (theoretical)<\/li><li>Doxorubicin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Eplerenone (theoretical)<\/li><li>Ergonovine (theoretical)<\/li><li>Ergotamine (theoretical)<\/li><li>Eszopiclone (theoretical)<\/li><li>Fentanyl (theoretical)<\/li><li>Ibrutinib (theoretical)<\/li><li>Irinotecan (theoretical)<\/li><li>Isavuconazonium Sulfate (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Lomitapide (theoretical)<\/li><li>Lovastatin (theoretical)<\/li><li>Lurasidone (probable)<\/li><li>Maraviroc (theoretical)<\/li><li>Methylergonovine (theoretical)<\/li><li>Midazolam (theoretical)<\/li><li>Naloxegol (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Pimozide (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Rifampin (theoretical)<\/li><li>Riociguat (theoretical)<\/li><li>Romidepsin (probable)<\/li><li>Sildenafil (theoretical)<\/li><li>Silodosin (probable)<\/li><li>Simvastatin (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Suvorexant (theoretical)<\/li><li>Tolvaptan (theoretical)<\/li><li>Trabectedin (theoretical)<\/li><li>Triazolam (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Vorapaxar (theoretical)<\/li><\/ul>"},{"id":"930276-s-4-14","title":"Major","mono":"<ul><li>Ado-Trastuzumab Emtansine (theoretical)<\/li><li>Afatinib (theoretical)<\/li><li>Alfentanil (theoretical)<\/li><li>Alprazolam (theoretical)<\/li><li>Aluminum Carbonate, Basic (established)<\/li><li>Aluminum Hydroxide (established)<\/li><li>Aluminum Phosphate (established)<\/li><li>Amiodarone (theoretical)<\/li><li>Amobarbital (theoretical)<\/li><li>Amprenavir (probable)<\/li><li>Apixaban (theoretical)<\/li><li>Aprepitant (theoretical)<\/li><li>Aprobarbital (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Armodafinil (theoretical)<\/li><li>Artemether (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Atazanavir (established)<\/li><li>Atorvastatin (theoretical)<\/li><li>Avanafil (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Bosentan (theoretical)<\/li><li>Bosutinib (theoretical)<\/li><li>Brentuximab Vedotin (theoretical)<\/li><li>Bromocriptine (theoretical)<\/li><li>Budesonide (theoretical)<\/li><li>Buprenorphine (theoretical)<\/li><li>Buspirone (theoretical)<\/li><li>Butabarbital (theoretical)<\/li><li>Butalbital (theoretical)<\/li><li>Cabazitaxel (established)<\/li><li>Cabozantinib (theoretical)<\/li><li>Calcium Carbonate (established)<\/li><li>Carbamazepine (theoretical)<\/li><li>Carvedilol (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Cilostazol (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Cladribine (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clobazam (theoretical)<\/li><li>Clofarabine (theoretical)<\/li><li>Clonazepam (theoretical)<\/li><li>Clozapine (established)<\/li><li>Cyclophosphamide (established)<\/li><li>Cyclosporine (theoretical)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Daclatasvir (theoretical)<\/li><li>Dactinomycin (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Daunorubicin (theoretical)<\/li><li>Delamanid (probable)<\/li><li>Delavirdine (probable)<\/li><li>Dexamethasone (theoretical)<\/li><li>Diazepam (theoretical)<\/li><li>Didanosine (established)<\/li><li>Digoxin (established)<\/li><li>Dihydroxyaluminum Aminoacetate (established)<\/li><li>Dihydroxyaluminum Sodium Carbonate (established)<\/li><li>Disopyramide (theoretical)<\/li><li>Docetaxel (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (theoretical)<\/li><li>Doxepin (theoretical)<\/li><li>Dutasteride (theoretical)<\/li><li>Efavirenz (theoretical)<\/li><li>Eletriptan (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Erlotinib (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Ethosuximide (theoretical)<\/li><li>Etoposide (theoretical)<\/li><li>Etravirine (theoretical)<\/li><li>Everolimus (theoretical)<\/li><li>Felodipine (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Fluticasone (theoretical)<\/li><li>Fosamprenavir (probable)<\/li><li>Fosaprepitant (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Glyburide (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Hydrocodone (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Ifosfamide (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imatinib (theoretical)<\/li><li>Isradipine (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ivacaftor (theoretical)<\/li><li>Ketoconazole (established)<\/li><li>Lapatinib (theoretical)<\/li><li>Letrozole (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Lidocaine (theoretical)<\/li><li>Lopinavir (probable)<\/li><li>Losartan (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Macitentan (theoretical)<\/li><li>Magaldrate (established)<\/li><li>Magnesium Carbonate (established)<\/li><li>Magnesium Hydroxide (established)<\/li><li>Magnesium Oxide (established)<\/li><li>Magnesium Trisilicate (established)<\/li><li>Mefloquine (theoretical)<\/li><li>Mephobarbital (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Methohexital (theoretical)<\/li><li>Methotrexate (theoretical)<\/li><li>Mexiletine (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Mitoxantrone (theoretical)<\/li><li>Modafinil (theoretical)<\/li><li>Montelukast (theoretical)<\/li><li>Morphine (theoretical)<\/li><li>Morphine Sulfate Liposome (theoretical)<\/li><li>Nafcillin (theoretical)<\/li><li>Nateglinide (theoretical)<\/li><li>Netupitant (theoretical)<\/li><li>Nevirapine (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Nimodipine (theoretical)<\/li><li>Nintedanib (theoretical)<\/li><li>Nisoldipine (theoretical)<\/li><li>Olaparib (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Oxaliplatin (theoretical)<\/li><li>Oxcarbazepine (theoretical)<\/li><li>Oxycodone (theoretical)<\/li><li>Paclitaxel (theoretical)<\/li><li>Palbociclib (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Pentobarbital (theoretical)<\/li><li>Perampanel (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Pioglitazone (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Pixantrone (theoretical)<\/li><li>Pomalidomide (theoretical)<\/li><li>Ponatinib (theoretical)<\/li><li>Prazosin (theoretical)<\/li><li>Prednisolone (theoretical)<\/li><li>Prednisone (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Regorafenib (theoretical)<\/li><li>Retapamulin (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifapentine (theoretical)<\/li><li>Rilpivirine (theoretical)<\/li><li>Ritonavir (probable)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Roflumilast (theoretical)<\/li><li>Rosuvastatin (established)<\/li><li>Rufinamide (theoretical)<\/li><li>Ruxolitinib (theoretical)<\/li><li>Salmeterol (theoretical)<\/li><li>Saquinavir (probable)<\/li><li>Saxagliptin (theoretical)<\/li><li>Secobarbital (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Simeprevir (theoretical)<\/li><li>Sirolimus (theoretical)<\/li><li>Sodium Bicarbonate (established)<\/li><li>Sumatriptan (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tadalafil (theoretical)<\/li><li>Tamoxifen (theoretical)<\/li><li>Tamsulosin (theoretical)<\/li><li>Telaprevir (established)<\/li><li>Telithromycin (theoretical)<\/li><li>Temsirolimus (theoretical)<\/li><li>Teniposide (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Thiopental (theoretical)<\/li><li>Ticagrelor (theoretical)<\/li><li>Tipranavir (probable)<\/li><li>Topiramate (theoretical)<\/li><li>Topotecan (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Tramadol (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Triamcinolone (theoretical)<\/li><li>Ulipristal (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Verapamil (theoretical)<\/li><li>Vilanterol (theoretical)<\/li><li>Vilazodone (theoretical)<\/li><li>Vinblastine (theoretical)<\/li><li>Vincristine (theoretical)<\/li><li>Vincristine Sulfate Liposome (theoretical)<\/li><li>Vinorelbine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Vortioxetine (theoretical)<\/li><li>Warfarin (theoretical)<\/li><li>Zaleplon (theoretical)<\/li><li>Zolpidem (theoretical)<\/li><\/ul>"},{"id":"930276-s-4-15","title":"Moderate","mono":"<ul><li>Indinavir (probable)<\/li><li>Nelfinavir (probable)<\/li><\/ul>"}]},{"id":"930276-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Diarrhea (12%), Nausea (16%)<\/li><li><b>Renal:<\/b>Proteinuria (39%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Endocrine metabolic:<\/b>Lactic acidosis<\/li><li><b>Gastrointestinal:<\/b>Pancreatitis<\/li><li><b>Hepatic:<\/b>Hepatitis B, Exacerbation, Hepatomegaly, With steatosis, Hepatotoxicity<\/li><li><b>Immunologic:<\/b>Immune reconstitution syndrome<\/li><li><b>Musculoskeletal:<\/b>Osteomalacia, Rhabdomyolysis<\/li><li><b>Renal:<\/b>Fanconi syndrome, Renal failure, Renal impairment, Renal tubular disorder, Proximal, Tubular necrosis, acute<\/li><\/ul>"},{"id":"930276-s-6","title":"Drug Name Info","sub":[{"id":"930276-s-6-17","title":"US Trade Names","mono":"Stribild<br\/>"},{"id":"930276-s-6-18","title":"Synonyms","mono":"Antiviral Combination<br\/>"},{"id":"930276-s-6-19","title":"Class","mono":"<ul><li>Anti-Infective Agent<\/li><li>Integrase Inhibitor<\/li><li>Nucleoside Reverse Transcriptase Inhibitor<\/li><li>Nucleotide Reverse Transcriptase Inhibitor<\/li><\/ul>"},{"id":"930276-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},{"id":"930276-s-6-21","title":"Generic Availability","mono":"No<br\/>"}]},{"id":"930276-s-7","title":"Mechanism Of Action","mono":"<ul><li>Elvitegravir, an integrase strand transfer inhibitor, prevents the integration of HIV-1 DNA into host genomic DNA. This leads to blocking the formation of the HIV-1 provirus and propagation of the viral infection.<\/li><li>Cobicistat is a selective CYP3A inhibitor, intended to increase the systemic exposure of CYP3A substrates such as elvitegravir. In cell culture studies, cobicistat has not demonstrated antiviral activity against HIV-1, hepatitis B virus, or hepatitis C virus, nor has it been found to antagonize the antiviral activity of elvitegravir, emtricitabine, or tenofovir.<\/li><li>Emtricitabine is a synthetic nucleoside analog of cytidine. The active metabolite, emtricitabine 5'-triphosphate, inhibits the activity of HIV-1 reverse transcriptase by competing with the natural substrate deoxycytidine 5'-triphosphate, which is then incorporated into nascent viral DNA resulting in chain termination. It is also a weak inhibitor of mammalian DNA polymerase alpha, beta, epsilon and mitochondrial DNA polymerase gamma.<\/li><li>Tenofovir disoproxil fumarate, an acyclic nucleoside phosphonate diester analog of adenosine monophosphate, is initially converted to tenofovir by diester hydrolysis and further undergoes phosphorylation by cellular enzymes to form tenofovir diphosphate. In turn, tenofovir diphosphate competes with deoxyadenosine 5'-triphosphate, which is then incorporated into DNA resulting in chain termination, thus, preventing the activity of HIV-1 reverse transcriptase. It is also a weak inhibitor of mammalian DNA polymerase alpha, beta, and mitochondrial DNA polymerase gamma.<\/li><\/ul>"},{"id":"930276-s-8","title":"Pharmacokinetics","sub":[{"id":"930276-s-8-23","title":"Absorption","mono":"<ul><li>Elvitegravir, Tmax, Oral: 4 hours<\/li><li>Cobicistat, Tmax, Oral: 3 hours<\/li><li>Emtricitabine, Tmax, Oral: 3 hours<\/li><li>Tenofovir, Tmax, Oral: 2 hours<\/li><li>Elvitegravir, Effect of food: 34% to 87% increased exposure (light snack or high fat)<\/li><li>Cobicistat, Effect of food: not significant<\/li><li>Emtricitabine, Effect of food: not significant<\/li><li>Tenofovir disoproxil fumarate, Effect of food: 24 to 23% increased exposure (light snack or high fat)<\/li><\/ul>"},{"id":"930276-s-8-24","title":"Distribution","mono":"<ul><li>Elvitegravir, Protein binding: 98% to 99%<\/li><li>Cobicistat, Protein binding: 97% to 98%<\/li><li>Emtricitabine, Protein binding: less than 4%<\/li><li>Tenofovir disoproxil fumarate, Protein binding: less than 0.7%<\/li><\/ul>"},{"id":"930276-s-8-25","title":"Metabolism","mono":"<ul><li>Elvitegravir, liver: extensive primarily via CYP3A<\/li><li>Elvitegravir: substrate of CYP3A and UGT 1A1\/3; a moderate CYP2C9 inducer<\/li><li>Cobicistat, liver: extensive primarily via CYP3A<\/li><li>Cobicistat: substrate of CYP3A and CYP2D6 (minor); inhibitor of CYP3A, CYP2D6, P-glycoprotein, BCRP, OATP1B1, and OATP1B3<\/li><li>Emtricitabine: not significantly metabolized.<\/li><li>Tenofovir: not significantly metabolized<\/li><\/ul>"},{"id":"930276-s-8-26","title":"Excretion","mono":"<ul><li>Elvitegravir, Renal: 6.7%<\/li><li>Cobicistat, Renal: 8.2%.<\/li><li>Emtricitabine, Renal: extensive<\/li><li>Tenofovir, Renal: extensive.<\/li><li>Elvitegravir, Fecal: 94.8%<\/li><li>Cobicistat, Fecal: 86.2%<\/li><li>Elvitegravir, Dialyzable: no (hemodialysis or peritoneal dialysis)<\/li><li>Cobicistat, Dialyzable: no (hemodialysis or peritoneal dialysis)<\/li><li>Emtricitabine, Dialyzable: Yes (hemodialysis), approximately 30% removed over 3 hours<\/li><li>Tenofovir disoproxil fumarate, Dialyzable: Yes (hemodialysis), approximately 10% removed in 4 hours<\/li><\/ul>"},{"id":"930276-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Elvitegravir: 12.9 hours<\/li><li>Cobicistat: 3.5 hours<\/li><li>Emtricitabine: 10 hours<\/li><li>Tenofovir: 17 hours<\/li><\/ul>"}]},{"id":"930276-s-9","title":"Administration","mono":"<b>General Information<\/b><br\/>administer with food <br\/>"},{"id":"930276-s-10","title":"Monitoring","mono":"<ul><li>Viral load: at baseline and with modification of antiretroviral (ARV) treatment, at 2 to 8 weeks; then every 4 to 8 weeks until values are below the limit of detection (less than 200 copies\/mL), then every 3 to 4 months; monitoring may be extended to every 6 months for patients who are immunologically stable, adherent, and with suppressed viral loads for more than 2 years<\/li><li>CD4 cell counts: at baseline and with modification of ARV treatment, then every 3 to 6 months during the at least the first 2 years of treatment and if the CD4 counts are below 300 cells\/mm(3) or viremia develops; after 2 years monitoring may be extended to every 12 months for patients who are clinically stable with suppressed viral loads<\/li><li>Hepatitis B screening: baseline and with modification of ARV treatment; may repeat screening if hepatitis B surface antigen or antibody are negative at baseline.<\/li><li>ALT, AST, and total bilirubin; at baseline and with modification of ARV treatment, at 2 to 8 weeks, then every 3 to 6 months; continue monitoring for several months after discontinuation in patients with underlying hepatic disease (eg, hepatitis B or C)<\/li><li>Basic chemistry, including serum sodium, potassium, bicarbonate, chloride, BUN, and creatinine; at baseline and with modification of ARV treatment, at 2 to 8 weeks, then every 3 to 6 months; serum phosphorus should be measured in patients at risk for renal impairment<\/li><li>Fasting blood glucose or HbA1c; at baseline and with modification of ARV treatment, then every 3 to 6 months with abnormal values or 12 months with normal values<\/li><li>CBC with a differential; at baseline and with modification of ARV treatment, then every 3 to 6 months<\/li><li>Fasting lipid profile; at baseline and with modification of ARV treatment, at 2 to 8 weeks, then every 6 to 12 months<\/li><li>Urinalysis; at baseline or modification of ARV treatment, then annually<\/li><li>Estimated CrCl at baseline and routinely thereafter; closely monitor patients experiencing a confirmed increase in serum creatinine of greater than 0.4 mg\/dL from baseline.<\/li><li>Chronic hepatitis B virus; at baseline<\/li><li>Bone mineral density in individuals with history of pathologic bone fracture or at risk for osteoporosis or bone loss<\/li><li>Signs and symptoms of hepatic dysfunction; several months following therapy discontinuation in patients co-infected with hepatitis B virus and HIV-1<\/li><\/ul>"},{"id":"930276-s-11","title":"How Supplied","mono":"<b>Stribild<\/b><br\/>Oral Tablet: (Cobicistat - Elvitegravir - Emtricitabine - Tenofovir Disoproxil Fumarate) 150 MG-150 MG-200 MG-300 MG<br\/>"},{"id":"930276-s-12","title":"Toxicology","sub":[{"id":"930276-s-12-31","title":"Clinical Effects","mono":"<b>AIDS ANTIVIRAL NUCLEOSIDES <\/b><br\/>USES: The nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs) are primarily used in the treatment of HIV-1 and HIV-2 infection. This class includes: emtricitabine, lamivudine, stavudine, abacavir, and tenofovir; zidovudine and didanosine are in this class but are covered in separate managements, and zalcitabine is no longer manufactured. These agents are also used in the treatment of hepatitis B infection and human T-lymphocyte virus (HTLV) 1 and 2. PHARMACOLOGY: The NRTIs terminate HIV RNA to DNA transcription by acting as substrates for the HIV reverse transcriptase and terminating DNA elongation. These agents prevent cell infection, but have no effect on already infected cells. TOXICOLOGY: Toxicological effects are generally extensions of adverse effects. EPIDEMIOLOGY: Overdose is uncommon and severe sequelae from acute overdose are rare. Adverse effects and drug interactions, however, are common. MILD TO MODERATE TOXICITY: There are limited data regarding overdose of NRTIs. However, overdose appears to be largely well tolerated with very few reports of severe clinical effects despite over 2 decades of drug availability. Nausea or vomiting, neurologic symptoms (ie, ataxia, lethargy, nystagmus, peripheral neuropathy), signs of bone marrow toxicity (ie, anemia, leukopenia, thrombocytopenia), or an increase in liver enzymes have all been reported in NRTI overdose or chronic toxicity. SEVERE TOXICITY: Severe toxicity has been reported after therapeutic use but not after acute overdose, and may be manifested by pancreatitis, hepatic steatosis, acute renal failure (ie, tenofovir), neuropsychiatric abnormalities, or acidosis. Chronic therapeutic administration may lead to mitochondrial toxicity leading to lactic acidosis, with or without hepatic microsteatosis. Pancreatitis, neuropathy, and myopathy often accompany the syndrome. Severe neuropsychiatric effects (ie, seizures, mania) have been reported. Lactic acidosis has been reported in patients receiving both single and dual nucleoside analogue (NRTI) regimens for HIV infection. This is thought to cause multiorgan failure and most commonly occurs in persons on prolonged (more than 6 months) therapy. ADVERSE EFFECTS: The most common adverse effects from all NRTIs are nausea, vomiting, headache, and malaise. Peripheral neuropathy and elevated transaminases have been reported with most NRTIs. Rash and hypersensitivity reactions are common and are usually self-limited when therapy is continued. Other adverse effects specific to each drug include: ABACAVIR: Hypersensitivity, nausea, vomiting, headache, and a possible increased risk of coronary artery disease. EMTRICITABINE: Rash, diarrhea, hypercholesterolemia, transaminitis, and mild rhabdomyolysis are common. Hepatic failure\/steatosis, neutropenia, and lactic acidosis are rare. LAMIVUDINE: Headache and nausea are common. Pancreatitis is rare. STAVUDINE: Peripheral neuropathy in greater than 60% of patients receiving over 4 mg\/kg daily. Lactic acidosis and transaminitis are common and do not require therapy or discontinuation unless severe. Dyslipidemia and insulin resistance have been associated with chronic stavudine and zidovudine. TENOFOVIR: Rash, headache, transaminitis, nausea, and vomiting are common. Hepatic failure\/steatosis, renal failure, rhabdomyolysis, pancreatitis, and lactic acidosis are rare. ZALCITABINE: Peripheral neuropathy, stomatitis, pancreatitis, transaminitis, and rash. <br\/>"},{"id":"930276-s-12-32","title":"Treatment","mono":"<b>AIDS ANTIVIRAL NUCLEOSIDES<\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Supportive therapy remains the mainstay of care. Benzodiazepines or antipsychotics may be used for agitation or manic symptoms. Mild transaminitis can be monitored, discontinuation of therapy is not usually necessary. Therapy should be changed for persistently rising transaminases or evidence of hepatic synthetic dysfunction. Nausea and vomiting should be treated with antiemetics. Peripheral neuropathies are generally reversible with drug withdrawal and can be treated with pain management as needed. Asymptomatic elevation of lactic acid without systemic acidemia does not require discontinuation of the medication. MANAGEMENT OF SEVERE TOXICITY: Supportive care is the mainstay of care. Aggressive fluid resuscitation should be initiated for severe lactic acidosis. Granulocyte colony stimulating factor may be considered for patients with agranulocytosis complicated by infection. Vasopressors may be necessary in cases with multi-organ failure. Withdrawal of the agent is imperative to improvement in severe adverse reactions. Riboflavin and L-carnitine may be useful in treating nucleoside reverse transcriptase inhibitor (NRTI)-associated lactic acidosis.<\/li><li>Decontamination: PREHOSPITAL: No prehospital decontamination is indicated. Prehospital care should focus on assessment of vital signs and general supportive care. HOSPITAL: Activated charcoal may be considered for patients that present early after overdose if they are awake, alert, and willing to drink the charcoal. Gastric lavage has no role in the management of NRTI overdose.<\/li><li>Airway management: Respiratory depression is not expected with overdose of NRTIs. However, coingestants must be considered and airway protection should be employed as needed for airway protection.<\/li><li>Antidote: There is no specific antidote for NRTI toxicity.<\/li><li>Acidosis: Treat severe metabolic acidosis (pH less than 7.1) with sodium bicarbonate 1 to 2 mEq\/kg. Anecdotal evidence suggests that riboflavin and L-carnitine may be useful in reversing NRTI-associated lactic acidosis. Riboflavin has been used at a dose of 50 mg\/day orally or intravenously. L-carnitine has been used at a dose of 50 mg\/kg\/day as a 2-hour infusion divided in 3 doses for patients not receiving dialysis, or a continuous infusion of 100 mg\/kg\/day in patients receiving dialysis.<\/li><li>Monitoring of patient: Monitor serum electrolytes and hepatic enzymes. Monitor serum lipase in patients with abdominal pain or severe acidosis. Lactic acid concentration and serum pH should be monitored in acidotic patients. Cardiac failure, likely due to acidosis, has been reported; therefore, cardiac monitoring is recommended in the setting of acidosis or chest pain. Sources of infection should be sought in patients with neutropenias or significant acidosis.<\/li><li>Enhanced elimination procedure: Hemodialysis and whole bowel irrigation have no role in the management of NRTI overdose.<\/li><li>Patient disposition: HOME CRITERIA: Suicidal patients and those with symptoms should be referred to a healthcare facility. Asymptomatic patients with inadvertent ingestion of NRTIs can be observed at home. OBSERVATION CRITERIA: Asymptomatic or mildly symptomatic patients should be observed for 4 to 6 hours, primarily monitoring signs of coingestant toxicity. ADMISSION CRITERIA: Patients with severe toxicity should be admitted. Patients with severe lactic acidosis, hepatic failure, or renal failure should be admitted to an intensive care setting. CONSULT CRITERIA: Infectious disease should be consulted if a change to anti-retroviral therapy is indicated. Consult a medical toxicologist for patients with severe toxicity or in whom the diagnosis is not clear.<\/li><\/ul>"},{"id":"930276-s-12-33","title":"Range of Toxicity","mono":"<b>AIDS ANTIVIRAL NUCLEOSIDES<\/b><br\/>TOXICITY: A full month supply of many of these agents has been ingested in overdose without clinical effects, though toxicity can occur at therapeutic doses with nucleoside reverse transcriptase inhibitors (NRTIs). LAMIVUDINE: No clinical signs or symptoms developed in an adult ingesting 6 grams of lamivudine. STAVUDINE: No acute toxicity was reported in patients treated with 12 to 24 times the recommended daily dosage. ZALCITABINE: PEDIATRIC: Overdoses of 1.5 mg\/kg have been reported; no sequelae developed. THERAPEUTIC DOSE: ABACAVIR: ADULT: 300 mg orally twice daily or 600 mg once daily. PEDIATRIC: 8 mg\/kg orally twice daily. EMTRICITABINE: ADULT: 200 mg\/day capsule, 240 mg\/day oral solution. PEDIATRIC: 0 to 3 months of age: 3 mg\/kg orally once daily; 3 months to 17 years of age: 6 mg\/kg once daily oral solution, up to a maximum of 240 mg; children weighing more than 33 kg and can swallow whole capsule: 200 mg once daily. LAMIVUDINE: ADULT: 150 mg orally twice a day or 300 mg once daily. PEDIATRIC: 0 to 28-days-old: 2 mg\/kg orally twice daily; 28 days or older: 4 mg\/kg orally twice daily, maximum 150 mg twice daily. STAVUDINE: ADULT: less than 60 kg: 30 mg orally every 12 hours; 60 kg or more: 40 mg orally every 12 hours. PEDIATRIC: 0 to 13-days-old: 0.5 mg\/kg\/dose orally every 12 hours; 14-days-old and less than 30 kg: 1 mg\/kg\/dose orally every 12 hours; 30 kg to less than 60 kg: 30 mg orally every 12 hours; 60 kg or more: 40 mg orally every 12 hours. TENOFOVIR: ADULT: 300 mg orally once daily. PEDIATRIC: at least 12-years-old and 35 kg or more: 300 mg orally once daily.<br\/>"}]},{"id":"930276-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to practice safe sex. Drug does not prevent disease transmission.<\/li><li>This drug may cause nausea, diarrhea, or fat redistribution.<\/li><li>Instruct patient to report signs\/symptoms of lactic acidosis (nausea, vomiting, abdominal pain, tachypnea) or hepatotoxicity (yellowing of the eyes or skin, light-colored stools, dark urine).<\/li><li>Advise patient to report signs\/symptoms of renal impairment or acute renal failure (nausea, vomiting, loss of appetite, changes in mental awareness).<\/li><li>Instruct patient not to breastfeed during treatment due to the potential for HIV transmission and risk for serious adverse reactions to the drug in the nursing infant.<\/li><li>Instruct patient to immediately report signs\/symptoms of infection.<\/li><li>Patient should take with food.<\/li><li>Advise patient against self-discontinuation of drug, especially if co-infected with hepatitis B.<\/li><li>Advise patient there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use (including over-the-counter and herbal drugs such as St. John's Wort).<\/li><li>Instruct patient to strictly adhere to the recommended dosing schedule (ie, avoid missing doses) to help control HIV infection and decrease HIV-related illnesses.<\/li><\/ul>"}]}